Regulação e modulação da secreção gástrica
Palavras-chave:
acido gastrico, acido cloridrico, preparações farmaceuticas, ulcera pepticaResumo
O aumento da secreção de ácido clorídrico, assim como alterações da integridade da mucosa e dos fatores de citoproteção gástrica podem contribuir para a patogênese multi fatorial da úlcera péptica. Atualmente, o tratamento desta doença é geralmente baseado na inibição da secreção ácida gástrica por bloqueadores do receptor H2 da histamina ou por inibição da bomba protônica ou, ainda, pelo uso de antimuscarínicos. O uso de medicamentos citoprotetores ficou restrito à carbenoxolona e ao misoprostol, que possuem diversas contra-indicações. Portanto, a pesquisa de agentes citoprotetores pode dar origem a drogas coadjuvantes ou mesmo a alternativas para o tratamento com anti-secretores.
Downloads
Referências
AI Moutaery AR, Tariq M. Effect of quinacrine, a phospholipase A, inhibitor on stress and chemically ineluced gastroluodenal ulcers. Digestion 1997; 58: 129-37.
Allen A, Flemstrom G, Garner A, Kivilaakso E. Gastroduodenal mucosa! protection. Physiol Rev 1993; 73: 823-57.
Andersson K, Linstrom E, Chen D, Monstein HJ, Boketoft A, Hakanson R. Depletion of enterochromaffin-like cell histamine increases histidine decarboxylase and chromogranin A mRNA leveis in rat stomach by a gastrin-independent mechanism. San d J Gastroenterol 1996; 31 :959-65.
Angus JÁ, Black JW. The interaction of choline esters, vagai stimulation and H2 receptor blockaele on acid secretion in vivo. Eur J Pharmacol 1982; 80:217-24.
Arquiola E, Guerra DG, Montiel L. A úlcera gastroduoelenal: história ele uma doença. Barcelona: Doyma, 1987.
Bauer RF, Bianchi RG, Casler J, Golc!stin B. Comparative mucosa! protective properties of misoprostol, cimetidine and sucralfate. Dig Dis Sei 1986; 31(2):81 S-5S.
Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H receptors. Nature 1972; 236:385-90.2
Barocelli E, lmpicciatore M. Study ofthe antisecretory and antiulcer mechanism of a new indenopirydazinone clerivative in rats. Pharmacol Res 1997; 35(5):487-92.
Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic anel pharmacokinetic propertiers and therapeutic potential in peptic ulcer elisease and Zollinger-Ellison syndrome. Drugs 1986; 32: 15-47.
Cover TL, Blaser MJ. Helicobacter pylori anel gastroduodenal disease. Annu Rev Med 1992; 43:135-45.
Ding XQ, Hakanson R. Evaluation of the specificity anel potency of series of cholecystokinin- 8/gastrin receptor antagonists in vivo. Pharmacol Toxicol 1996; 79:124-30.
Eberhart CE, Dubois RN. Eicosanoides anel gastrointestinal tract. Gastroenterol 1995; 109: 285- 301.
Elliot SN, MsKinignt W, Cirino G, Wallace JL. A nitric oxide-releasing nonesteroidal anti-intlarnatory drug accelerates gastric ulcer healing in rats. Gastroenterol 1995; l 09:524-30.
Felix WL,Miller JC, Guth PH. Dissociated effects of misoprostol on gastric acid secretion anel mucosa!bloocl flow. Dig Dis Sei 1986; 31(2 Suppl Feb ):86S-90S.
Goodwin CS. Helicobacter pylori gastritis, peptic ulcer, and gastric cancer: clinicai and molecular aspects. Clin Infec Dis 1997; 25: 1O 17-19.
Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96:615-25.
Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand? Am J Gastroenterol 1996; 91(10):2080-6.
Hermansson M, Stael Von Holstein C, Hostettmann K. Peptic ulcer perforation before and after the - receptor blockers and protonintroduction of H2 pump inhibitor. Scan J Gastroenterol 1997; 32:523-9.
Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995; 75(1 ): 155-88.
HirschowitzBl,KellingD, Lewin M, Okabe S, Parsons M, Sewing K, et al. Phannacological aspects of acid secretion. DigDis Sei 1995; 40(2):3S-23S.
Hojgaard L, Nielson AM, Rune SL. Peptic Ulcer Pathophysiology: acic, bicarbonate, and mucosa! function. Scan J Gastroenterol 1996; 3 l(Suppl 216): 10-5.
Kato S, KitamuraM, Korolkiewicz RP, Takeuchi K. Role of nitric oxide in regulation of gastric acid secretion in rats: effects of NO donors and NO synthase inhibitor. Br J Pharmacol 1998; 123(5):839-46.
Kato S, Yayoi A, Konishi M, Kuroda N, Takeuchi K. Mechanism of gastric hyperemic response during acid secretion in rats: relation to nitric oxide,prostaglandins, and sensory neurons. J Clin Gastroenterol 1997;25(Suppl 1):48-55.
Katori M, Majima M. Multiple roles of inducible cyclooxigenase-2 and its selective inhibitors. Nippon YakurigakuZasshi 1997; 109(6):247-58.
KonturekPC,Brzozowski T,Kontirek SI,MárquezM, Torres J, Ortiz JA. Studies on the cytoprotective and antisecretory activity of ebrotidine: a review. Arzneimittelforschung 1997; 47( 4 A): 578-89.
Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994;89:116-128.
Martin MJ, La Casa C. Anti-oxidant mechanisms involved in gastroprotective effects of quercetin. Z Naturforsch 1998; 53(1-2): 82-8.
Saiam O A, Szolecsányi J,MózsikG. Capsaicin and the stomach: a review of experimental and cl inical data. J Physiol 1997;91:151-71.
Tari A, Ramada M, Kamiyasu T, Sumii K, Haruma K, Inoue M, et al. Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients. Dig Dis Sei 1997;42(8): 1741-6.
Vuyyuru L, Schubert ML, Harrington L, Arimura A, MakhloufGM. Dual inhibitory pathways link antral somatostatina and histamine secretion in human, dog, and rat stomach. Gastroenterology 1995; 109:1566-74.
